Trial Profile
A 52-Week Treatment, Multi-Center, Randomized, Open Label, Parallel Group Study to Assess the Long Term Safety and Efficacy of Indacaterol (300 microg o.d.) Using Salmeterol (50 microg b.i.d.) as an Active Control in Japanese Patients With Chronic Obstructive Pulmonary Disease(COPD)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2022
Price :
$35
*
At a glance
- Drugs Indacaterol (Primary) ; Salmeterol
- Indications Chronic obstructive pulmonary disease
- Focus Adverse reactions; Registrational
- 11 Jan 2022 New source identified and integrated Japan Pharmaceutical Information Center - Clinical Trials Information (JapicCTI090737).
- 24 Nov 2010 Actual end date (Nov 2010) added as reported by ClinicalTrials.gov.
- 24 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.